Agilent Technologies, Inc. (NYSE:A) Stake Held by Meag Munich Ergo Kapitalanlagegesellschaft MBH

Meag Munich Ergo Kapitalanlagegesellschaft MBH held its position in shares of Agilent Technologies, Inc. (NYSE:A) during the second quarter, Holdings Channel reports. The firm owned 15,473 shares of the medical research company’s stock at the end of the second quarter. Meag Munich Ergo Kapitalanlagegesellschaft MBH’s holdings in Agilent Technologies were worth $908,000 as of its most recent filing with the SEC.

A number of other institutional investors have also made changes to their positions in A. BlackRock Inc. raised its position in shares of Agilent Technologies by 1,946.9% in the first quarter. BlackRock Inc. now owns 23,119,219 shares of the medical research company’s stock worth $1,222,310,000 after buying an additional 21,989,739 shares in the last quarter. JPMorgan Chase & Co. boosted its position in Agilent Technologies by 31.4% in the first quarter. JPMorgan Chase & Co. now owns 8,366,511 shares of the medical research company’s stock worth $442,338,000 after buying an additional 1,999,376 shares during the last quarter. MARSHALL WACE ASIA Ltd purchased a new position in Agilent Technologies during the first quarter worth about $58,065,000. Marshall Wace North America L.P. purchased a new position in Agilent Technologies during the first quarter worth about $58,065,000. Finally, FMR LLC boosted its position in Agilent Technologies by 3.9% in the first quarter. FMR LLC now owns 21,588,407 shares of the medical research company’s stock worth $1,141,379,000 after buying an additional 803,993 shares during the last quarter.

Shares of Agilent Technologies, Inc. (NYSE:A) traded up 0.28% during midday trading on Friday, reaching $60.08. The company had a trading volume of 1,236,434 shares. The stock has a 50-day moving average of $60.04 and a 200 day moving average of $54.90. Agilent Technologies, Inc. has a 52 week low of $42.92 and a 52 week high of $61.84. The firm has a market capitalization of $19.31 billion, a price-to-earnings ratio of 33.77 and a beta of 1.30.

Agilent Technologies (NYSE:A) last released its quarterly earnings results on Monday, May 22nd. The medical research company reported $0.58 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.48 by $0.10. The company had revenue of $1.10 billion during the quarter, compared to analyst estimates of $1.05 billion. Agilent Technologies had a return on equity of 16.49% and a net margin of 13.41%. The firm’s revenue was up 8.1% on a year-over-year basis. During the same quarter last year, the business posted $0.44 earnings per share. On average, analysts anticipate that Agilent Technologies, Inc. will post $2.23 earnings per share for the current year.

The business also recently declared a quarterly dividend, which was paid on Wednesday, July 26th. Investors of record on Monday, July 3rd were given a $0.132 dividend. The ex-dividend date was Thursday, June 29th. This represents a $0.53 annualized dividend and a yield of 0.88%. Agilent Technologies’s dividend payout ratio is currently 29.78%.

A has been the subject of a number of research reports. Robert W. Baird upped their price objective on Agilent Technologies from $57.00 to $62.00 and gave the stock an “outperform” rating in a report on Wednesday, May 24th. Deutsche Bank AG reiterated a “buy” rating and issued a $58.00 price objective (up from $56.00) on shares of Agilent Technologies in a report on Sunday, April 2nd. Morgan Stanley upped their price objective on Agilent Technologies from $65.00 to $70.00 and gave the stock an “overweight” rating in a report on Wednesday, May 24th. Zacks Investment Research upgraded Agilent Technologies from a “hold” rating to a “buy” rating and set a $63.00 price objective for the company in a report on Tuesday, May 16th. Finally, BidaskClub cut Agilent Technologies from a “strong-buy” rating to a “buy” rating in a report on Tuesday, June 13th. Two analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company. Agilent Technologies presently has an average rating of “Buy” and a consensus target price of $60.12.

In related news, insider Patrick Kaltenbach sold 5,000 shares of Agilent Technologies stock in a transaction dated Thursday, July 13th. The stock was sold at an average price of $61.26, for a total value of $306,300.00. Following the completion of the transaction, the insider now owns 45,138 shares in the company, valued at $2,765,153.88. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Michael R. Mcmullen sold 32,511 shares of Agilent Technologies stock in a transaction dated Monday, May 1st. The stock was sold at an average price of $55.48, for a total value of $1,803,710.28. Following the completion of the transaction, the chief executive officer now owns 260,346 shares of the company’s stock, valued at approximately $14,443,996.08. The disclosure for this sale can be found here. In the last quarter, insiders sold 150,119 shares of company stock valued at $8,823,719.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. The Company serves the life sciences, diagnostics and applied chemical markets. It has three business segments: life sciences and applied markets business, diagnostics and genomics business, and Agilent CrossLab business.

Want to see what other hedge funds are holding A? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agilent Technologies, Inc. (NYSE:A).